A beta-3 adrenoceptor agonist has recently been approved for treatment of overactive bladder symptoms.34,35 One conference abstract,36 and 2 published papers37,38 provided relevant information on the common rs4994 missense mutation, of which 2 could be included in metaanalysis. Here, ADRB3 is linked to overactive bladder.